

A copy of the Minutes of The Annual General Meeting of Shareholders 2021 of Thainakarin Hospital Public Company Limited.

Time and place

The Annual General Meeting 2021 was held on Thursday, 18th November 2021; at 14.00 hours on 4th Floor Meeting Room A, Thainakarin Hospital Building, No. 345, Debaratna Road., km 3.5 Bangna-Nuea, Bangna Bangkok with the attendees as follows:

Name of directors who attended the meeting

1. Charoen	Meensook, M.D.	Chairman of the Board
2. Mr. Thiti	Sihanatkathakul	Director
3. Mr. Prapat	Suthawate	Director
4. Mr. Sumeth	Jeniesda	Director
5. Arkom	Cheirsilpa, M.D.	Director
6. Mr. Pitipat	Sihanatkathakul	Director
7. Mr. Norathep	Sihanatkathakul	Director
8. Mr. Tosaporn	Sihanatkathakul	Director
9. Mr. Kraisak	Kadkum	Director, Independent Director and Chairman of the Audit Committee
10. Pridi	Hetrakul, M.D.	Director, Independent Director and Member of the Audit Committee
11. Assoc. Prof. Panya	Issarawornrawanich, Ph.D.	Director, Independent Director and Member of the Audit Committee
12. Mr. Chailerg	Viriyarattanaporn	Director, Independent Director and Member of the Audit Committee

Name of directors who did not attend the meeting

1. Prof. Emeritus Deja	Tanphaichitra, M.D.	Director
2. Assoc. Prof. Chertsak	Dhiraputra, M.D.	Director, Independent Director and Member of the Audit Committee

Name of executives who attended the meeting

1. Prof. Pittayapoom	Pattaranutaporn, M.D.	Deputy Chief Executive Officer
2. Rear Admiral Surachet	Suphanich, M.D.	Hospital Director and Acting Administrative Director
3. Mrs. Nampetch	Saraggananda	Deputy Medical Director - Nursing
4. Mr. Issaret	Khuandamrongtham	Deputy Administrative Director - Finance and Accounting and Company Secretary

Name of the auditor who attended the meeting

1. Mr. Samran	Taengcham	Auditor, EY Office Limited
---------------	-----------	----------------------------

Name of the person who was invited to attend the meeting

1. Col. Dan	Tanphaichitra, M.D.	
-------------	---------------------	--

The Meeting commenced at 14.00 hours.

Miss Thanarat Charoenrath, designated as the moderator, introduced the Company's directors, Executives and Invitees attending the meeting. However, There were 2 members of the Board of directors unable to attend the meeting due to illness, namely Prof. Emeritus Deja Tanphaichitra, M.D. and Assoc. Prof. Chertsak Dhiraputra, M.D. Due to the epidemic situation of the Coronavirus Disease 2019, the Company was highly aware and concerned for the health of all shareholders attending the meeting, including those who participated in organizing this meeting. The Company would strictly comply with various government measures to prevent and reduce the risk of spreading the coronavirus disease 2019. For this reason, the Company changed the format of the Annual General Meeting of Shareholders to be a shareholders' meeting via electronic media, following the rules stipulated in the law relating to arrangements via electronic media. After that Miss Thanarat explained the regulations as well as the Company's Articles of Association and criteria relating to the general meeting of shareholders, as per the following details:

1	Quorum of shareholders	The meeting shall commence only when there were not less than 25 shareholders and proxies or not less than one-half of the total shareholders present at the meeting, and must represent an aggregate of not less than one-third of the total shares sold.
2	Procedures for conducting the meeting in accordance with the agenda	The meeting must be conducted according to the sequence of agenda specified in the meeting notice, unless the Meeting had resolved to change the sequence by the votes of not less than two-thirds of the shareholders and proxies present at the meeting.
3	Meeting agenda other than those specified in the meeting notice	When the Meeting had considered all the agenda items specified in the meeting notice, the shareholders and proxies holding an aggregate of not less than one-third of the total shares sold had the right to request the Meeting to consider any matters other than those specified in the meeting notice, where one share was counted as one vote.
4	Vote counting	Shareholders had the number of votes equal to the number of shares held.
5	Voting method	Voting shall be conducted openly with a ballot paper. A secret ballot could be done upon a request of not less than 5 shareholders and approval of the Meeting by the majority vote of the shareholders and proxies present at the meeting, where one share was counted as one vote. The Chairman of the meeting shall specify the method for secret voting, which, at this meeting, was to be done by anonymous ballot paper.
6	Meeting resolution	Resolution was passed by the majority vote of the shareholders and proxies present at the meeting and entitled to vote. The number of votes was equal to the number of shares held, and one share was counted as one vote. In case of a tie vote, the Chairman of the meeting shall exercise a casting vote.

7	Meeting resolution regarding director election	In voting on the director election agenda, the shareholders and proxies present at the meeting might exercise all their votes to elect one or several persons as director(s), but could not split their votes to any person in any number.
8	Meeting resolution regarding payment of director remunerations	Resolution was passed by the votes of not less than two-thirds of the total votes of the shareholders and proxies present at the meeting and entitled to vote.
9	In case shareholders has a special interest in the matter considered	If any shareholders and proxies had a special interest in a matter, such shareholders and proxies shall have no right to vote on that matter.

For the year 2021, the Company used the registration and votecasting system through an electronic meeting by INVENTECH SYSTEMS (THAILAND) CO., LTD., in conducting this meeting. Miss Thanarat explained the voting procedures and questions asked at the meeting. (Presentation on screen) In the case of vote counting, only the shareholders and proxies who voted against, abstained, and invalid ballots would be counted. The said votes will be deducted from the total number of votes, and the votes of the rest of the meeting attendees will be regarded as the votes in favor of that agenda.

Criteria for approval resolutions in particular agenda items were as follows:

1. Agendas 1, 3 and 9 For acknowledgement only.
2. Agendas 2, 4, 5, 6 and 8 Approval resolution must be passed by the majority vote of the shareholders and proxies present at the meeting and entitled to vote.
3. Agenda 7 Approval resolution must be passed by the votes of not less than two-thirds of the total votes of the shareholders and proxies present at the meeting and entitled to vote.

The Company has informed the shareholders that the invitation to and notification of the meeting had been conducted by 3 means as follows:

1. Delivery of the meeting notice by mail;
2. Publication on newspaper;
3. Publication on the Company's website.

Miss Thanarat, designated as the moderator, informed the Meeting that there were 20 shareholders holding a total of 36,653,701 shares present in person, and 20 shareholders holding a total of 83,114,300 shares present by proxy. In total, there were 40 shareholders, representing 119,768,001 shares or equivalent to 66.54% of the total 180,000,000 shares sold, which constituted a quorum in accordance with the laws and the Company's Articles of Association. The Meeting could thus commence.

After the explanation, Miss Thanarat started proceeding with the agenda items according to the sequence.

Agenda 1 General update by the President

- No matter to inform the meeting -

Miss Thanarat informed the Meeting that Agenda 1 was for acknowledgement and thus required no vote casting.

Agenda 2 To consider and approve the minutes of the Annual General Meeting of Shareholders 2020 held on 19th November 2020

The Chairman requested the Meeting to approve the minutes of the Annual General Meeting of Shareholders 2020 was held on 19th November 2020 as per a copy of the minutes submitted to the shareholders together with the invitation notice.

After the clarification by the Chairman, there was no further question. The Meeting was then requested to pass a resolution.

Miss Thanarat described the criteria for vote casting on Agenda 2 that it must be approved by the majority vote of the shareholders and proxies present at the meeting and entitled to vote.

Resolution: The Meeting considered and resolved to approve the minutes of the Annual General Meeting of Shareholders 2020 held on 19th November 2020, as follows:

	Vote		%
Approved	119,768,505	Votes	100.0000
Disapproved	0	Votes	0.0000
Abstained	0	Votes	0.0000
Invalid ballot	5	Votes	0.0000

Agenda 3 To consider and acknowledge the Annual Report 2021 of the Company

The Chairman proposed that the Meeting consider the Company's Annual Report 2021 in a QR code Format as per Attachment 2 which had been submitted to the shareholders together with the invitation notice. In addition, the Board of Directors had considered report as accurate. The consideration of the Meeting was then requested.

After there was no further question, the Chairman requested the Meeting to consider and pass a resolution.

Miss Thanarat informed the Meeting that Agenda 3 was for acknowledgement and thus required no vote casting.

Agenda 4 To consider and approve the auditor's report and the financial statements for the year ended 31st July 2021 audited by the auditors of EY Office Limited

The Chairman assigned Mr. Issaret Khuandamrongtham, Deputy Administrative Director - Finance and Accounting and Company Secretary, to provide the Meeting with explanations regarding the consideration and approval of the auditor's report and the Company's financial statements for the year ended 31st July 2021, which had been audited by the auditors of EY Office Limited.

Mr. Issaret reported the essential financial information for the year ending July 31, 2021.

1. Total assets increased by 305 million baht; the composition is as follows:

- 129.56 million baht in cash, bank deposits, and fixed deposits;
- Trade accounts receivable, especially for COVID-19 medical expenses pending disbursement from the National Health Security Office (NHSO) 102 million baht and 22 million baht from emergency and critical illness cases, Supra Contract and Endoscopic Retrograde Cholangiopancreatography (ERCP). The rests are counterparties and insurance companies, as usual.
- Other current assets of 14.5 million baht from the subscription money for the Moderna brand of alternative vaccines paid to the Pharmaceutical Organization for which the Company was allocated a total of 13,140 doses.
- Land, buildings, and equipment increased from related factors, namely
 - Replacement of elevators and escalators totaling 23.41 million baht.
 - Critical medical devices include a CT 128-Slice, worth 15.70 million baht; replacing the original 64-Slice device, and ophthalmic medical devices, totaling 10.37 million baht, such as glaucoma analyzer and retinal imaging, vitreous surgery, and treatment of eye diseases with laser light, intraocular lens measuring machine without contacting the eye, including 4D Ultrasound of the obstetrics; and gynecology department, totaling 6.4 million baht.
- Assets under construction include a car park building and a radiation therapy center building, totaling 45.25 million baht.
- Land leasehold rights decreased by 22 million baht, and amortization of 30-year long-term land leasehold benefits from the Thai Red Cross Society.

2. Total liabilities increased by 88 million baht with the following components:

- Accounts payable increased by 35 million baht due to the acceleration of reserves of medicines and medical supplies with high usage rates during the COVID-19 epidemic, and there may be a shortage.
- Income tax payable increased by 15 million baht due to increased profit, and in 2021, no tax incentive measure can deduct additional expenses if invested in machinery as in 2020.
- Other current liabilities increased in the amount of 33.4 million baht, which was the advance received from the service users for the subscription for alternative vaccines (Moderna).

3. Shareholders' equity increased by 218 million baht.

- Operating profit of 293.40 million baht and other comprehensive income due to changes in provisions, employee benefits, and related deferred tax of 9.4 million baht deducted with dividends paid during December 2020 amounting to 80 million baht, the impact of financial reporting standards, and a group of financial instruments that make it necessary to consider the expected credit losses of new trade accounts receivable.

4. Profit and loss

- Medical expenses increased by 35 million baht. The Company managed costs effectively, causing the gross profit margin in 2021 to be 25.90%, an improvement from the previous year at 23.97%. Sales and management are at a constant level. Part of the positive factor is the policy for people infected with COVID-19 to be quarantined in hospitals for 14 days, resulting in an increase in inpatient bed occupancy rates from 49.17% to 71.74%.

5. Financial ratio

- Overall the Company can maintain liquidity, operational efficiency, and the ability to make profits except for the debt collection period, which arises from the NHSO debtors and has to wait for the government budget review, as explained earlier.

Subsequently, there was no further question. The Chairman then requested the Meeting to consider and pass a resolution.

Miss Thanarat described the criteria for vote casting on Agenda 4 that it must be approved by the majority vote of the shareholders and proxies present at the meeting and entitled to vote.

Resolution: The Meeting considered and resolved to approve the auditor's report and the Company's financial statements for the year ended 31st July 2021 which had been audited by the auditors of EY Office Limited by the votes as follows:

	Vote		%
Approved	119,264,305	Votes	99.58
Disapproved	504,200	Votes	0.42
Abstained	0	Votes	0.0000
Invalid ballot	0	Votes	0.0000

Agenda 5 To consider and approve profit allocation and dividend payment for the year 2021

Miss Thanarat informed the Meeting that the Board of Directors had viewed that the Company's net profit for 2021 as of 31st July 2022 amounted to Baht 293,415,820 (Baht Two Hundred Ninety-Three Million Four hundred and Fifteen Thousand Eight Hundred and Twenty Only) and proposed the Meeting to consider and approve dividend payment for the operating results from 1st August 2020 to 31st July 2021 at the rate of Baht 0.50 (Fifty satang) per share, totaling Baht 90,000,000 (Baht Ninety Million Only). The dividend payment shall be made to the shareholders whose names were listed on the record date of 29th November 2021. The date of payment was 15th December 2021.

Information on dividend payments from 2016-2021 was presented on screen at the Meeting.

Year	Revenue (M. Baht)	Net Profit (M. Baht)	Dividend/Share (Baht)	Total Dividend Amount (M. Baht)	Dividend Payment Date
2021	2,063.08	239.41	0.50	90	15 th Dec 2021
2020	2,037.47	256.33	0.45	81	16 th Dec. 2020
2019	2,185.07	317.53	0.55	99	19 th Dec. 2019
2018	2,164.27	356.06	0.60	108	13 th Dec. 2018

Mr. Piyapong Prasartthong, a shareholder, came in person and asked if the Company's net profit was from providing alternative vaccines or not.

Prof. Pittayapoom said the Company's profits are in line with the Company's activities. The modern vaccine is likely to be for the private sector; other vaccines are government-sourced vaccines that the Company provides to the people according to the guidelines of the Ministry of Health, which the Company does not get any profit from it.

When there was no further question, the Chairman requested the Meeting to consider and pass a resolution.

Miss Thanarat described the criteria for vote casting on Agenda 5 that it must be approved by the majority vote of the shareholders and proxies present at the meeting and entitled to vote.

Resolution: The Meeting considered and resolved to approve dividend payment for the operating results from 1st August 2020 to 31st July 2021 at the rate of Baht 0.50 (Fifty satang), totaling Baht 90,000,000 (Baht Ninety Million Only). The dividend payment shall be made to the shareholders whose names were listed on the record date of 29th November 2021. The date of payment was 15th December 2021.

	Vote		%
Approved	119,768,505	Votes	100.0000
Disapproved	0	Votes	0.0000
Abstained	0	Votes	0.0000
Invalid ballot	5	Votes	0.0000

Agenda 6 To consider the re-election of Directors replacing Directors who retired by rotation and amend the authority of the Directors (if any):

Miss Thanarat informed the Meeting that Section 71 of the Public Limited Companies Act and Article 18 of the Company's Articles of Association stipulated that one-third of the Company's directors shall retire from office and the directors retiring by rotation could be re-elected. Presently, 5 directors from the total 14 directors were due to retire by rotation, but Prof. Emeritus Deja Tanphaichitra, M.D., a director who is due to retire by rotation does not wish to return to the position. Therefore, the Board of director proposes to the meeting to consider appointing 4 directors who are retired by rotation in another term and propose to the meeting to consider appointing 1 new director as follows:

1. Mr. Prapat Suthawate Director
2. Mr. Norathep Sihanartkatakul Director
3. Mr. Tosaporn Sihanatkathakul Director
4. Mr. Chailerg Viriyarattanaporn Director, Independent Director and Member of the Audit Committee
5. Col. Dan Tanphaichitra, M.D. The person proposed for appointment as a new director

After the clarification by the Chairman, there was no further question. The Meeting was then requested to consider and pass a resolution.

Miss Thanarat described the criteria for vote casting on Agenda 6 that it must be approved by the majority vote of the shareholders and proxies present at the meeting and entitled to vote.

Resolution: The Meeting considered and resolved to elect directors, as follows

1	Mr. Prapat Suthawate	Director		
			Vote	%
Approved			119,255,205	99.57
Disapproved			513,300	0.43
Abstained			0	0.00
Valid ballot			0	0.00

2	Mr. Norathep Sihanartkatakul	Director		
			Vote	%
Approved			119,255,205	99.57
Disapproved			513,300	0.43
Abstained			0	0.00
Valid ballot			0	0.00

3 Mr. Tosaporn Sihanatkathakul Director			
	Vote		%
Approved	119,255,205	Votes	99.57
Disapproved	513,300	Votes	0.43
Abstained	0	Votes	0.00
Valid ballot	0	Votes	0.00

4 Mr. Chailerg Viriyarattanaporn Director, Independent Director and Member of the Audit Committee			
	Vote		%
Approved	119,255,205	Votes	99.57
Disapproved	513,300	Votes	0.43
Abstained	0	Votes	0.00
Valid ballot	0	Votes	0.00

5 Col. Dan Tanphaichitra, M.D. Director			
	Vote		%
Approved	119,255,205	Votes	99.57
Disapproved	513,300	Votes	0.43
Abstained	0	Votes	0.00
Valid ballot	0	Votes	0.00

Agenda 7 To consider and determine remunerations of the Company's directors and Audit Committee members

Miss Thanarat presented the remunerations of the Company's directors and Audit Committee members in the previous year on screen, and explained that the Board of Directors had scrutinized the remunerations based on various suitability issues. The Board deemed it appropriate to propose that the Meeting consider and determine remunerations of the Company's directors and Audit Committee members for the year 2022 at the rates (the same as 2021) as follows:

Attendance fees for the Board of Directors' Meeting

- Chairman of the Board Baht 18,000 per meeting
- Directors Baht 14,000 per meeting

Attendance fees for Audit Committee's Meeting

- Chairman of the Audit Committee Baht 18,000 per meeting
- Audit Committee Members Baht 14,000 per meeting

Medical care allowance for the Company's Director, Audit Committee Members and their families shall not exceed Baht 800,000 per person (the same as 2020).

Subsequently, there was no further question. The Meeting was then requested to consider and pass a resolution.

Miss Thanarat described the criteria for vote casting on Agenda 7 that it must be approved by the votes of not less than two-thirds of the total votes of the shareholders and proxies present at the meeting and entitled to vote.

Resolution: The Meeting considered and resolved to approve the remunerations of the Company's Directors and Audit Committee Members for the year 2021 as proposed by the Board of Directors, by the votes as follows:

	Vote		%
Approved	81,959,505	Votes	100.00
Disapproved	0	Votes	0.00
Abstained	0	Votes	0.00
Invalid ballot	0	Votes	0.00

Such votes exceeded two-thirds of the total votes of the shareholders and proxies present at the meeting and entitled to vote.

Agenda 8 To consider and approve appointment of auditors, and to determine auditors' fee for the accounting period from 1st August 2021 to 31st July 2022

Miss Thanarat informed the Meeting that the Board of Directors had considered and deemed it appropriate to appoint the certified public accountants of EY Office Limited, namely:

- Mrs. Sarinda Hirunprasurtwutti CPA No. 4799, or
- Ms. Patcharawan Koonarangsri CPA No. 6650, or
- Mr. Samran Taengcham CPA No. 8021

to be the Company's auditors for the year 2022 for the accounting period from 1st August 2021 to 31st July 2022, with the remunerations of Baht 1,170,000. Said remunerations comprised the financial statement review fee for 1st-3rd quarters of Baht 125,000 per quarter, the annual financial statement audit fee of Baht 795,000, which same as 2021, and the auditing-related expenses based on the actual cost but not exceeding Baht 30,000.

Subsequently, there was no further question. The Chairman then requested the Meeting to consider and pass a resolution.

Miss Thanarat described the criteria for vote casting on Agenda 8 that it must be approved by the majority vote of the shareholders and proxies present at the meeting and entitled to vote.

Resolution: The Meeting considered and resolved to appoint:

- Mrs. Sarinda Hirunprasurtwutti CPA No. 4799, or
- Ms. Patcharawan Koonarangsri CPA No. 6650, or
- Mr. Samran Taengcham CPA No. 8021

to be the Company's auditors for the year 2022 for the accounting period from 1st August 2021 to 31st July 2022, with the remunerations of Baht 1,170,000 and the auditing-related expenses based on actual cost but not exceeding Baht 30,000, by the votes as follows:

	Vote		%
Approved	119,768,505	Votes	100.00
Disapproved	0	Votes	0.00
Abstained	0	Votes	0.00
Invalid ballot	0	Votes	0.00

Agenda 9 Report on the Construction Project of Thainakarin Hospital 2

The Chairman assigned Mr. Prapat Suthawate to report on the progress of the Thainakarin Hospital 2 Project.

Mr. Prapat Suthawate, the Chairman of the working group, informed about the construction of Thainakarin Hospital 2 from the approval of the investment budget for the Thainakarin Hospital 2 project 4,318 million baht from the shareholders' meeting. He reported the progress of the construction project of Thainakarin 2 Hospital, which consists of the following buildings:

- **Parking building**
 - 9-story building with one basement floor, one elevator, parking for 264 cars, total construction area of 9,958 sq.m.
 - Project value 90,404,410 baht
 - Construction began on May 1, 2021
 - Scheduled for completion on February 28, 2022
- Linac Center
 - 3-story building with two elevators, construction area 1,740 sq m.
 - Project value 63,471,250 baht
 - Construction began on June 12, 2021
 - Scheduled for completion on April 11, 2022
- **Thainakarin Hospital 2 Building**
 - In the process of preparing information to support the preliminary construction drawing.

In this regard, Mr. Tosaporn provided additional information about the construction of the said project.

Mr. Tosaporn reported the progress of the parking building and the Linac Center. The details are as follows:

1. Parking Building

Construction Contractor: Jomtakol Co., Ltd

Current work progress: 21.71%, 3.46% behind schedule.

The progress of the main category:

• Construction preparation work	100%	
• Piling work	100%	
• Foundation concrete work	100%	
• Basement concrete work	100%	
• Retaining wall work	100%	
• Infrastructure work, 1 st Floor	80%	20%
• Infrastructure work, 2 nd Floor	75%	25%
• Infrastructure work, 3 rd Floor	75%	25%
• Infrastructure work, 4 th Floor	40%	60%

The next step will be to build up to the 9th Floor and to be completed by the end of February (with pictures of the progress on the screen).

2. Linac Center

Construction Contractor: Jomtakol Co., Ltd.

Current work progress: at 52%

The progress of the main category:

• Construction preparation work	100%
• Piling work	100%
• Foundation concrete work	100%
• Infrastructure work, 1 st Floor	100%
• Radiology room wall work	100%
• Infrastructure work, 2 nd Floor	80%
• Infrastructure work, 3 rd Floor	75%

A radiology room is being prepared to prepare a Linear Accelerator (LINAC) machine to enter the area. The structure of this room has been handed over to the Company that sold the device. When all structural work is completed, the interior decoration process will start in January next year and finish in April, as informed.

Subsequently, there was no further question. The Chairman then requested the Meeting to consider and pass a resolution.

Miss Thanarat informed the Meeting that Agenda 9 was for acknowledgement and thus required no vote casting.

Agenda 10 To consider other matters (if any)

Mr. Chaiwat Sriwongcharoen, the shareholder, came in person and inquired about the reasons for the change in position or resignation of the Chief Financial Officer (CFO) several times in the past year.

Mr. Thiti said the Company had made a prudent decision under the competition situation in which recruiting for key roles is challenging. The Company makes every effort to ensure that the Chief Accounting and Financial Officer (CFO) who will assume a position in the Company will be able to benefit the Company and all shareholders to the fullest extent.

Mr. Chaiwat Sriwongcharoen, a shareholder who came in person, inquired whether the hospital still operates a special ward (Hospitel) or not under the current situation.

Prof. Pittayapoom said COVID-19 is new in public health. The predictions are not only in Thailand but also at a global level which is still unpredictable. On the European side, the 5th wave of the epidemic has already occurred, so COVID -19 may not be gone from Thailand. The hospital can be well controlled during this time. However, there is still uncertainty about possible future situations, such as the emergence of new clusters, the opening of countries, or tourism. Therefore, the hospital's strategy is to take care of patients who are both regular patients, Thai and foreign patients, as well as being prepared at all times. As for the hospital, there are still patients in the hospital's hospitel, thus showing that the hospital is ready to help patients suffering from COVID -19. It is still unpredictable when COVID -19 will come back to spread another wave again. But if the epidemic is reduced and there is no epidemic, then Hospitel will have to disappear according to the trend of COVID - 19.

Mr. Niyom Jungsthitkul, a shareholder who came in person, asked about Thainakarin 2 Hospital's project and the preparation plans. Therefore, he would like to ask for clear progress because the hospital has informed us that it has been collecting and studying information since last year's shareholder meeting. The first construction drawings were presented at the shareholders' meeting three years ago. It can be seen from the start of more private hospitals opening for service nearby. If it continues to be delayed, there is a fear of losing the competitive edge.

Prof. Pittayapoom clarified that, first of all, business planning considers the global economy and Thailand's economic situation. In the face of the COVID -19 crisis, the economic recovery will be worse than the U-shape, which does not know what will happen. Economists have also said that the recovery will be a K-shape, meaning a partial recovery of the economy. Secondly, looking at the industry is that the medical industry will find more competition. It affects patients' purchasing power and those who use public health services.

Most importantly, COVID -19 has created a new normal and has changed, such as the Company's shareholders' meeting in Electronic format, building new corridors, and rebuilding elevators to make safety by separating those at risk and those who are sterile. The hospital has to change the service model and new waiting instead of waiting in outpatient departments. The key is bringing technology to use in Telemedicine, Smart Hospitals, and the upcoming Digital Hospital, which the hospital must plan carefully. The hospital promises to continue to operate these. Thainakarin Hospital 2 project is still there and will be implemented. What is being done at this time, whether it be a radiotherapy center or other short-term projects, are essential things planned to support the upcoming Thainakarin Hospital 2 project. Therefore, it requires the greatest prudence and flexible strategic planning. In this regard, the shareholders should be confident that the Company has been carefully considered.

Mr. Keeratika Panglad, as a proxy, suggested that Agenda 3: Acknowledgement of the annual report, the Company should also present a summary overview in the presentation of this agenda.

Mr. Kraisak accepted the shareholders' suggestions for consideration in the next general meeting of shareholders.

Subsequently, there was no further question.

The Chairman declared the meeting closed at 15.33 hours.



(Charoen Meensook, M.D.)
Chairman of the Meeting

Mr. Prapat Suthawate / Mr. Attapong Tipaksorn
Ms. Budsara Vikyanont

Company Secretary
Minutes Taker